Rapid and specific ex-vivo diagnosis of central nervous system lymphoma

Abstract

Disclosed are methods of detecting and treating suspected B-cell lymphoma.

1 . A method of detecting the presence of B-cell lymphoma in a tumor sample from a subject, the method comprising:
 contacting the tumor sample with an aptamer comprising at least 90% sequence identity to SEQ ID NO. 1, wherein the aptamer comprises a detectable label, to create a treated tumor sample;   washing the treated tumor sample; and   imaging the treated tumor sample, wherein the presence of the labeled aptamer is indicative of B-cell lymphoma.   
     
     
         2 . The method of  claim 1 , wherein the tumor is one or more of a brain tumor, a spinal cord tumor, an eye tumor, a meningeal tumor, or a leptomeningeal tumor. 
     
     
         3 . The method of  claim 1 , wherein tumor sample comprises a biopsy section. 
     
     
         4 . The method of  claim 1 , wherein the aptamer has a concentration of between 0.3 μM and 3 μM, inclusive. 
     
     
         5 . The method of  claim 1 , wherein the tumor sample is contacted with the aptamer for between 5 and 20 minutes, inclusive. 
     
     
         6 . The method of  claim 1 , wherein the tumor sample is contacted with an agent to block nonspecific binding in addition to the aptamer. 
     
     
         7 . The method of  claim 6 , wherein the agent to block nonspecific binding is yeast transfer RNA (tRNA). 
     
     
         8 . The method of  claim 1 , wherein the label is a fluorescent label, luminescent label, radioisotopic label, or a label that comprises an enzyme capable of a colorimetric conversion of a substrate. 
     
     
         9 . The method of  claim 1 , wherein the subject has a brain tumor, the tumor sample comprises a fresh biopsy section, the aptamer is SEQ ID NO: 1 and comprises a fluorescent label, and the method, including imaging, is completed in 20 minutes or less. 
     
     
         10 . A method of treating B-cell lymphoma in a subject in need thereof, the method comprising:
 contacting a tumor sample from the subject with an aptamer with at least 90% sequence identity to SEQ ID NO. 1, wherein the aptamer comprises a detectable label, to create treated sample, washing the treated tumor sample, imaging the treated tumor sample, and treating the patient based on the presence or absence of aptamer in the treated tumor sample.   
     
     
         11 . The method of  claim 10 , wherein imaging the treated tumor sample reveals the presence of aptamer staining, wherein treating the subject comprises a surgical or non-surgical medical intervention. 
     
     
         12 . The method of  claim 10 , wherein the aptamer has a concentration of between 0.3 μM and inclusive. 
     
     
         13 . The method of  claim 10 , wherein the tumor sample comprises a biopsy section and the biopsy sections are contacted with the aptamer for between 5 and 20 minutes, inclusive and contacted with yeast transfer RNA (tRNA) in addition to the aptamer. 
     
     
         14 . The method of  claim 10 , wherein the tumor comprises a brain tumor. 
     
     
         15 . A method of preparing a tumor sample for imaging, the method comprising:
 contacting the tumor sample with an aptamer comprising at least 90% sequence identity to SEQ ID NO. 1, wherein the aptamer comprises a detectable label, to create a treated tumor sample; and   washing the treated tumor sample.   
     
     
         16 . The method of  claim 15 , wherein the tumor comprises a brain tumor. 
     
     
         17 . The method of  claim 15 , wherein tumor sample comprises a biopsy section. 
     
     
         18 . The method of  claim 15 , wherein the aptamer has a concentration of between 0.3 mM and 3 mM, inclusive. 
     
     
         19 . The method of  claim 15 , wherein the aptamer has a concentration of between 0.3 μM and 1 μM, inclusive. 
     
     
         20 . The method  claim 15 , wherein the tumor sample contacted with the aptamer for between 5 and 10 minutes, inclusive.